TIMELESS deficiency sensitizes thyroid cancer to cisplatin treatment via the DNA damage repair pathway
The newly identified signaling involving circadian rhythm genes and DDR pathways provided mechanistic insights into the cisplatin sensitization strategy in thyroid cancer. Therefore, TIMELESS may be a promising target in thyroid cancer therapeutics.
Authors
- Juyong Liang (ORCID: https://orcid.org/0000-0003-0063-3847)
- Boke Liu
- Yang Dai (ORCID: https://orcid.org/0000-0003-1489-9080)
- Chaoyu Wang (ORCID: https://orcid.org/0000-0002-0988-1444)
- Ping Yuan (ORCID: https://orcid.org/0000-0003-2027-0510)
Institutions
- Ruijin Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Guizhou Provincial People's Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.tranon.2025.102504
- Primary Topic
- Circadian rhythm and melatonin
- Type
- article
- Field-Weighted Citation Impact
- 0.00